Home / Inspections / 1304368

FDA Inspection 1304368 — Hikma Pharmaceuticals USA Inc.

Hikma Pharmaceuticals USA Inc. — FEI 2220525

The FDA completed an inspection of Hikma Pharmaceuticals USA Inc. on May 13, 2026 in Cherry Hill, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.

Inspection Details

Classification
No Action Indicated (NAI) (NAI)
End Date
May 13, 2026
Fiscal Year
2026
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Cherry Hill, NJ (United States)

Facility

Other inspections at this facility

  • 1237333 (VAI Wed Jun 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1222115 (VAI Fri Nov 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1176451 (NAI Thu Jul 07 2022 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1106822 (VAI Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1067645 (NAI Fri Sep 14 2018 00:00:00 GMT+0000 (Coordinated Universal Time))

FDA data resources